Date: Thursday, June 23, 2016
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: We developed the nanoherbaceutical formulation and evaluated against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson’s disease (PD) model.
Background: PD is a progressive neurodegenerative disorder allied with the deficit of dopamine in the central nervous system. Currently available therapies are able to bring symptomatic relief to PD patients, but still the strategies for delaying disease progression without any untoward effects are lagging behind. Under these circumstances a multi-target and multi drug based approach of plant based therapies are the only way out to find the more cure from this disease.
Methods: In our study, we have developed the nanoherbaceutical formulation by combining the extracts of Huperzia serrata, Mucuna pruriens and Withania somnifera (1:2:1) and further we have chosen nanosuspension as a delivery system for nanoherbaceutical. Nanoherbaceutical suspension was prepared by using top-down technique. Statistical optimization and validation was done by using response surface methodology. Drug release from the prepared nanoherbaceutical was found to be almost 10 times faster. Experimental subjects were treated with MPTP for 2 week to showed the biochemical and physiological abnormalities similar to Parkinson’s disease patients. We confirmed that the MPTP led to physiological deficits, behavioral abnormalities, reduction of dopamine and its metabolites, depletion of antioxidant such as glutathione peroxidase (GPx) glutathione (GSH) and superoxide dismutase (SOD) activity, and the enhanced level of thiobarbituric acid reactive substance (TBARS).
Results: MPTP control group showed the altered level of DA, DOPAC, HVA, GSH, GPx and TBARS level compared to normal control. Along with this, physiological abnormalities were seen in the toxic group. Oral treatment of nanoherbaceutical resulted increase level of DA, DOPAC, HVA and normalized the level of TBARS in the brain region of animals. An improved motor function was observed after 14 days treatment with the nanoherbaceutical. Along with these, an increased GSH and GPx levels in the brain region was observed as compared to untreated brain region.
Conclusions: Our findings clearly indicate that the nanoherbaceutical better control the progression of disease and consider as alterantive to current available therapies.
To cite this abstract in AMA style:V. Kumar, P.C. Bhatt. Development of a nanoherbaceutical formulation containing compound extracts from huperzia serrata, mucuna pruriens and withania somnifera for the prevention and treatment of Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/development-of-a-nanoherbaceutical-formulation-containing-compound-extracts-from-huperzia-serrata-mucuna-pruriens-and-withania-somnifera-for-the-prevention-and-treatment-of-parkinsons-disease/. Accessed March 1, 2024.
« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/development-of-a-nanoherbaceutical-formulation-containing-compound-extracts-from-huperzia-serrata-mucuna-pruriens-and-withania-somnifera-for-the-prevention-and-treatment-of-parkinsons-disease/